Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

3.61
-4.1000-53.18%
Post-market: 3.630.0198+0.55%19:59 EDT
Volume:86.12M
Turnover:304.97M
Market Cap:292.80M
PE:-2.89
High:3.83
Open:2.98
Low:2.90
Close:7.71
Loading ...

Altimmune selloff on MASH data overdone, says H.C. Wainwright

TIPRANKS
·
14 hours ago

BUZZ-Altimmune set for worst day ever after underwhelming data for liver disease drug

Reuters
·
Yesterday

Altimmune Down Over 56%, On Track for Largest Percent Decrease Since February 2017 -- Data Talk

Dow Jones
·
Yesterday

Altimmune Shares Fall 59.3% After Co Reports Mid-Stage Data for Liver Disease Drug

THOMSON REUTERS
·
Yesterday

Stock Track | Altimmune Plummets 61.61% Despite Positive MASH Trial Results; Fibrosis Improvement Misses Mark

Stock Track
·
Yesterday

Altimmune Exec Says Based on FDA Guidance Reduction of Mash With High Level of Statistical Significance Alone Would Be Sufficient for Approval - Conf Call

THOMSON REUTERS
·
Yesterday

Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution

MT Newswires Live
·
Yesterday

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Reuters
·
Yesterday

Altimmune Shares Fall Over 50% Premarket; Co Announces Trial Results of Its Drug for a Liver Disease

THOMSON REUTERS
·
Yesterday

BRIEF-Altimmune Announces Positive Topline Results From The Impact Phase 2B Trial Of Pemvidutide

Reuters
·
Yesterday

Stock Track | Altimmune Plunges 6.49% Pre-market Despite Positive MASH Trial Results

Stock Track
·
Yesterday

Altimmune Inc: Trial Met Its Primary Endpoint

THOMSON REUTERS
·
Yesterday

Altimmune Inc - Trial Achieves 59.1% Mash Resolution Without Worsening Fibrosis

THOMSON REUTERS
·
Yesterday

Altimmune Inc - Weight Loss of up to 6.2% at 24 Weeks in Trial

THOMSON REUTERS
·
Yesterday

Altimmune Announces Positive Topline Results From the Impact Phase 2B Trial of Pemvidutide in the Treatment of Mash

THOMSON REUTERS
·
Yesterday

Altimmune Shares Rise on Liver Disease Trial Data Presentation

Dow Jones
·
Yesterday

Altimmune to announce Topline 24 week results from Phase 2b trial of Pemvidutide

TIPRANKS
·
Yesterday

Altimmune to Announce Topline 24 Week Results From Its Impact Phase 2B Trial of Pemvidutide in the Treatment of Mash on Thursday, June 26

THOMSON REUTERS
·
Yesterday

This Week's Unlock Schedule: BLAST, VENOM, SOON to Experience One-Time Large Unlock

Blockbeats
·
23 Jun

Upbit 24-hour Trading Volume Rankings: XRP, BTC, and ETH Take the Top Three Spots

Blockbeats
·
19 Jun